Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

4.99USD
15 Dec 2017
Change (% chg)

$0.30 (+6.40%)
Prev Close
$4.69
Open
$4.79
Day's High
$5.04
Day's Low
$4.52
Volume
535,479
Avg. Vol
168,466
52-wk High
$16.65
52-wk Low
$1.41

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Sep '17 1.55 -0.556
Jun '17 1.15 -0.677
Mar '17 1.02 -0.603
FY 2016 Dec '16 4.06 -0.376
Sep '16 1.72 -0.537
Jun '16 1.45 -0.473
Mar '16 1.16 -0.870
FY 2015 Dec '15 1.23 -0.415
Sep '15 1.20 -0.488
Jun '15 1.07 0.004
Mar '15 0.81 -0.319
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Dec-17 3 1.42 1.60 1.10 2.00
Quarter Ending Mar-18 1 1.03 1.03 1.03 0.00
Year Ending Dec-17 3 5.14 5.32 4.82 2.53
Year Ending Dec-18 3 2.46 5.37 0.00 4.75
Earnings (per share)
Quarter Ending Dec-17 3 -0.68 -0.61 -0.72 -0.62
Quarter Ending Mar-18 2 -0.60 -0.49 -0.70 -0.61
Year Ending Dec-17 3 -2.56 -2.44 -2.69 -2.40
Year Ending Dec-18 4 -2.51 -1.89 -2.99 -2.74
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 88.66 32.93
P/E High - Last 5 Yrs. -- 290.77 45.62
P/E Low - Last 5 Yrs. -- 93.67 24.34
Beta -- 0.85 0.88
Price to Sales (TTM) 6.98 100.68 5.40
Price to Book (MRQ) 1.08 13.50 5.38
Price to Tangible Book (MRQ) 1.08 13.43 6.78
Price to Cash Flow (TTM) -- 76.24 23.45
% Owned Institutions 74.37 6.25 1.40

Dividends

  Company industry sector
Dividend Yield -- 0.29 1.50
Dividend Yield - 5 Year Avg -- 0.28 1.52
Dividend 5 Year Growth Rate -- 1.88 5.17
Payout Ratio(TTM) -- 17.26 43.76

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -20.95 433.88 9.00
Sales (TTM) vs TTM 1 Yr. Ago 57.47 75.04 5.38
Sales - 5 Yr. Growth Rate -- 33.47 10.33
EPS (MRQ) vs Qtr. 1 Yr. Ago -43.17 30.81 19.67
EPS (TTM) vs TTM 1 Yr. Ago 2.39 -- --
EPS - 5 Yr. Growth Rate -- 43.18 10.79
Capital Spending - 5 Yr. Growth Rate -- 40.71 15.25

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 1.68 2.18
Current Ratio (MRQ) 5.65 5.36 2.98
LT Debt to Equity (MRQ) 0.00 18.93 11.56
Total Debt to Equity (MRQ) 0.00 20.59 15.81
Interest Coverage (TTM) -177.45 -111.94 33.29

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -- 38.73 54.83
Gross Margin - 5 Yr. Avg. -- 51.18 52.40
EBITD Margin (TTM) -660.33 -- --
EBITD - 5 Yr. Avg -- -261.13 15.24
Operating Margin (TTM) -664.11 -556.69 7.76
Operating Margin - 5 Yr. Avg. -- -279.31 10.75
Pre-Tax Margin (TTM) -657.71 -529.93 8.57
Pre-Tax Margin - 5 Yr. Avg. -- -279.05 11.17
Net Profit Margin (TTM) -657.71 -531.37 4.88
Net Profit Margin - 5 Yr. Avg. -- -282.22 7.47
Effective Tax Rate (TTM) -- 23.72 23.11
Effective Tax Rate - 5 Yr. Avg. -- 19.13 24.00

Efficiency

  Company industry sector
Revenue/Employee (TTM) 111,873 25,316,769 864,680,848
Net Income/Employee (TTM) -735,803 3,332,346 101,718,394
Receivable Turnover (TTM) 18.26 21.54 5.76
Inventory Turnover (TTM) -- 2.01 3.34
Asset Turnover (TTM) 0.15 0.37 0.93

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -97.82 -0.77 11.00
Return on Assets - 5 Yr. Avg. -- -0.26 12.43
Return on Investment (TTM) -123.49 2.36 14.46
Return on Investment - 5 Yr. Avg. -- 2.98 16.28
Return on Equity (TTM) -127.78 2.96 16.05
Return on Equity - 5 Yr. Avg. -- 6.41 17.51
  1 Year 3 Year 5 Year
Sales % 94.43 94.41 --
EPS (TTM) % -68.75 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Proteostasis Therapeutics Inc

Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 68.84%
# of Holders: 53
Total Shares Held: 17,358,980
3 Mo. Net Change: -1,310,417
# New Positions: 5
# Closed Positions: 19
# Increased Positions: 20
# Reduced Positions: 29
# Net Buyers: -9
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.